Mergers and Acquisitions

In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.

Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.

H.I.G. Capital’s portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals.

Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion.

Actylis combines Aceto and its 10 acquired specialists into a singular global brand.

Avance Clinical’s acquisition of C3 Research Associates expands its CRO services to North America.

ChargePoint Technology has acquired single-use container company PuroVaso.

Catalent will acquire Metrics Contract Services for $475 million to expand high-potent capabilities and oral development and manufacturing capacity.

Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).

CRYOPDP is expanding its footprint to Spain with its acquisition of Polar Expres.

GSK has completed its demerger of Haleon and has signed an agreement to help support future pandemic preparedness in Europe.

As a result of the disruptions caused by the COVID-19 pandemic, global arbitration has adapted to a ‘new normal’.

Boehringer Ingelheim has signed an option to acquire Trutino Biosciences.

Advanz Pharma has signed an agreement with Intercept Pharmaceuticals to acquire most of the its subsidiaries and non-US operations.

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9 billion.

Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.

Pfizer plans to acquire ReViral and its respiratory syncytial virus therapeutic candidates to strengthen Pfizer’s capabilities in infectious disease research.

Stanley Capital has announced the acquisition of MyMeds&Me by its portfolio company Drug Safety and Pharmacovigilance Services Solutions.

Emmes has acquired Casimir, marking its fourth major acquisition.

Biocon Biologics will acquire Viatris’ global biosimilars business, including the company’s portfolio of in-licensed biosimilar assets, in a transaction valued at over $3.3 billion.

Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.

Sartorius Stedim Biotech has completed the acquisition of the chromatography equipment division of Novasep.

pharmasol has completed the strategic merger with PharmaLex.

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Merger with Phlexglobal expands provider’s technological capabilities.

PharmaLex Group has merged with MAP Group, broadening its market access expertise and extending its reach into the Italian marketplace.

After a previously announced merger, Protagen Protein Services, BioAnalytix, and GeneWerk have formed a new CRO under the name ProtaGene.

The acquisition of Protein Metrics expands Insightful Science’s R&D solutions to include proteomics.

BBI Solutions has completed the acquisition of BioTeZ Berlin-Buch—a Germany-based manufacturer of reagents and finished tests for the in-vitro diagnostics market.